This is a Phase II, open-label, multicenter, prospective study of MGTA-145 + plerixafor mobilized HLA-matched sibling and matched unrelated donor allografts for myeloablative hematopoietic stem cell transplantation (HSCT) in recipients with hematological malignancies. Donors will undergo 1 or 2 days of mobilization and apheresis.
- acute myeloid leukemia (AML)
- aplastic anemia
- graft versus host disease (GVHD)
- myelodysplastic syndromes (MDS)